Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.

Yann Neuzillet (1) , Xavier Tillou (2) , Romain Mathieu (3) , Jean-Alexandre Long (4) , Marc Gigante (5) , Philippe Paparel (6) , Laura Poissonnier (6) , Hervé Baumert (7) , Bernard Escudier (8) , Hervé Lang (9) , Nathalie Rioux-Leclercq (10) , Pierre Bigot (11) , Jean-Christophe Bernhard (12) , Laurence Albiges (8) , Laurence Bastien (13) , Jacques Petit (2) , Fabien Saint (2) , Franck Bruyere (14) , Jean-Michel Boutin (14) , Nicolas Brichart (14) , Georges Karam (15) , Julien Branchereau (15) , Jean-Marie Ferriere (12) , Hervé Wallerand (12) , Sébastien Barbet (12) , Hicham Elkentaoui (12) , Jacques Hubert (16) , Benoit Feuillu (16) , Pierre-Etienne Theveniaud (16) , Arnauld Villers (17) , Laurent Zini (17) , Aurélien Descazeaux (18) , Morgan Roupret (19) , Benoit Barrou (19) , Karim Fehri (19) , Thierry Lebret (1) , Jacques Tostain (5) , Jean-Etienne Terrier (5) , Nicolas Terrier (4) , Lucille Martin (20) , Fabrice Dugardin (21) , Ismaël Galliot (21) , Frédéric Staerman (22) , Marie-Dominique Azemar (22) , Jacques Irani (23) , Baptiste Tisserand (23) , Marc-Olivier Timsit (24) , Federico Sallusto (25) , Pascal Rischmann (25) , Laurent Guy (26) , Antoine Valeri (27) , Charles Deruelle (27) , Abdel-Rahmène Azzouzi (11) , Denis Chautard (11) , Arnaud Mejean (24) , Laurent J. Salomon (28) , Jérôme Rigaud (15) , Christian Pfister (21) , Michel Soulié (25) , François M. Kleinclauss (20) , Lionel Badet (6) , Jean-Jacques Patard (29)

1 Service d'urologie
2 Service d'urologie
3 Service d'urologie [Rennes] = Urology [Rennes]
4 Service d'urologie
5 Service d'Urologie - Andrologie [CHU Saint-Etienne]
6 Service d'urologie [Centre Hospitalier Lyon Sud - HCL]
7 Service d'urologie
8 Département de médecine oncologique [Gustave Roussy]
9 Service d'urologie
10 Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes]
11 Service d'urologie
12 Service d'urologie, andrologie et transplantation rénale
13 IMRB - Institut Mondor de recherche biomédicale
14 Service d'urologie [Tours]
15 Service d'urologie
16 Service d'Urologie [CHRU Nancy]
17 Service d'urologie
18 Service de Chirurgie urologique et andrologie [CHU Limoges]
19 CHU Pitié-Salpêtrière [AP-HP]
20 Service d'urologie, andrologie et transplantation rénale
21 Service d'urologie [Rouen]
22 URCA - Université de Reims Champagne-Ardenne
23 Service d'urologie
24 Service d'urologie
25 Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse]
26 Service d'urologie
27 Service d'urologie
28 Service d'urologie [Mondor]
29 Service d'urologie

BACKGROUND: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. OBJECTIVE: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. DESIGN, SETTING, AND PARTICIPANTS: Twenty-four French university departments of urology participated in this retrospective study. INTERVENTION: All patients were treated according to current European Association of Urology guidelines. MEASUREMENTS: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. RESULTS AND LIMITATIONS: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥ 3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. CONCLUSIONS: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.

Domaines: Urologie et Néphrologie; Cancer

Yann Neuzillet, Xavier Tillou, Romain Mathieu, Jean-Alexandre Long, Marc Gigante, et al.. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.. European Urology, 2011, 60 (2), pp.366-73. ⟨10.1016/j.eururo.2011.02.035⟩. ⟨inserm-00577215⟩